- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Bone Marrow Research
Volume 2012 (2012), Article ID 375075, 8 pages
CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients
1Department of Clinical Immunology, L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Rudolfa Weigla Street, 53-114 Wroclaw, Poland
2Lower Silesian Center for Cellular Transplantation, National Bone Marrow Donor Registry, Grabiszyńska 105, 53-439 Wroclaw, Poland
Received 28 July 2012; Revised 24 September 2012; Accepted 24 September 2012
Academic Editor: Bronwen Shaw
Copyright © 2012 Emilia Jaskula et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- P. Ljungman, “Risk assessment in haematopoietic stem cell transplantation: viral status,” Best Practice and Research, vol. 20, no. 2, pp. 209–217, 2007.
- International Standards for Cellular Therapy Product Collection, Processing, and Administration, chapter 6, FACT-JACIE Standards, 4th edition, 2008.
- J. W. Gratama, J. W. J. Van Esser, C. H. J. Lamers et al., “Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection,” Blood, vol. 98, no. 5, pp. 1358–1364, 2001.
- H. T. Maeker and V. C. Maino, “Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry,” Human Immunology, vol. 65, no. 5, pp. 493–499, 2004.
- M. Sester, B. C. Gärtner, U. Sester, M. Girndt, N. Mueller-Lantzsch, and H. Köhler, “Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity,” Transplantation, vol. 76, no. 8, pp. 1229–1230, 2003.
- J. D. Roback, “CMV and blood transfusions,” Reviews in Medical Virology, vol. 12, no. 4, pp. 211–219, 2002.
- M. Boeckh and W. G. Nichols, “The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy,” Blood, vol. 103, no. 6, pp. 2003–2008, 2004.
- W. G. Nichols, L. Corey, T. Gooley, C. Davis, and M. Boeckh, “High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection,” Journal of Infectious Diseases, vol. 185, no. 3, pp. 273–282, 2002.
- P. B. McGlave, X. O. Shu, W. Wen et al., “Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program,” Blood, vol. 95, no. 7, pp. 2219–2225, 2000.
- P. Ljungman, K. Larsson, G. Kumlien et al., “Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors,” Scandinavian Journal of Infectious Diseases, vol. 34, no. 5, pp. 347–350, 2002.
- P. Ljungman, R. Brand, H. Einsele, F. Frassoni, D. Niederwieser, and C. Cordonnier, “Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis,” Blood, vol. 102, no. 13, pp. 4255–4260, 2003.
- E. Jaskula, D. Dlubek, D. Duda, K. Bogunia-Kubik, A. Mlynarczewska, and A. Lange, “Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4+ lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients,” Biology of Blood and Marrow Transplantation, vol. 15, no. 10, pp. 1296–1305, 2009.
- E. Jaskula, D. Dlubek, M. Sedzimirska, D. Duda, A. Tarnowska, and A. Lange, “Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation,” Transplantation Proceedings, vol. 42, no. 8, pp. 3273–3276, 2010.